Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.
The Myasthenia Gravis – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.
Key Targets in the Myasthenia Gravis Pipeline Drugs Market
The key targets in the Myasthenia Gravis pipeline drugs market are Complement C5, IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Acetylcholinesterase, Complement Factor D, Tumor Necrosis Factor Receptor Superfamily Member 5, and 5-Hydroxytryptamine Receptor 3 among others.
Myasthenia Gravis Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Myasthenia Gravis Pipeline Drugs Market
The key mechanisms of action in the Myasthenia Gravis pipeline drugs market are Complement C5 Inhibitor, IgG Receptor FcRn Large Subunit p51 Inhibitor, Cells Expressing B Lymphocyte Antigen CD20 Inhibitor, Acetylcholinesterase Inhibitor, Complement Factor D Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Inhibitor, and 5-Hydroxytryptamine Receptor 3 Inhibitor.
Myasthenia Gravis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Myasthenia Gravis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Myasthenia Gravis pipeline drugs market are Subcutaneous, Intravenous, Oral, Inhalational, Intravenous Drip, Ophthalmic, and Parenteral.
Myasthenia Gravis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Myasthenia Gravis Pipeline Drugs Market
The key molecule types in the Myasthenia Gravis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Modified Cell Therapy, Synthetic Peptide, and Biologic among others.
Myasthenia Gravis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Myasthenia Gravis Pipeline Drugs Market
The major companies in the Myasthenia Gravis pipeline drugs market are Akari Therapeutics Plc (Akari), Alexion Pharmaceuticals Inc (Alexion), Alpha Cancer Technologies Inc (ACT), Amneal Pharmaceuticals Inc (Amneal), and Argenx SE (argenx) among others.
Myasthenia Gravis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Myasthenia Gravis Pipeline Drugs Market Overview
| Key Targets | Complement C5, IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Acetylcholinesterase, Complement Factor D, Tumor Necrosis Factor Receptor Superfamily Member 5, and 5-Hydroxytryptamine Receptor 3 |
| Key Mechanisms of action | Complement C5 Inhibitor, IgG Receptor FcRn Large Subunit p51 Inhibitor, Cells Expressing B Lymphocyte Antigen CD20 Inhibitor, Acetylcholinesterase Inhibitor, Complement Factor D Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Inhibitor, and 5-Hydroxytryptamine Receptor 3 Inhibitor |
| Key Routes of Administration | Subcutaneous, Intravenous, Oral, Inhalational, Intravenous Drip, Ophthalmic, and Parenteral |
| Key molecule types | Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Modified Cell Therapy, Synthetic Peptide, and Biologic |
| Major companies | Akari Therapeutics Plc (Akari), Alexion Pharmaceuticals Inc (Alexion), Alpha Cancer Technologies Inc (ACT), Amneal Pharmaceuticals Inc (Amneal), Johnson and Johnson, and Argenx SE (argenx) |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myasthenia Gravis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myasthenia Gravis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Myasthenia Gravis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Amneal Pharmaceuticals Inc
Amplo Biotechnology Inc
AnTolRx Inc
Argenx SE
Beijing Mabworks Biotech Co Ltd
BioMarin Pharmaceutical Inc
BioXpress Therapeutics SA
Cabaletta Bio Inc
Cartesian Therapeutics Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
CSL Ltd
CuraVac Inc
Cytodyn Inc
DAS Therapeutics Inc
HanAll Biopharma Co Ltd
Horizon Therapeutics Plc
ImmunAbs Inc
Johnson & Johnson
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Ltd
Medytox Inc
MetVital Inc
NeoProgen Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
NMD Pharma AS
Novartis AG
Oak Hill Bio Inc
Pfizer Inc
PlateletBio
Principia Biopharma Inc
Protalex Inc
Ra Pharmaceuticals Inc
Rallybio Corp
ReceptoPharm Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Taxon Therapeutics Ltd
Toleranzia AB
UCB SA
Yantai Rongchang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Myasthenia Gravis pipeline drugs market?
The key targets in the Myasthenia Gravis pipeline drugs market are Complement C5, IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Acetylcholinesterase, Complement Factor D, Tumor Necrosis Factor Receptor Superfamily Member 5, and 5-Hydroxytryptamine Receptor 3.
-
What are the key mechanisms of action in the Myasthenia Gravis pipeline drugs market?
The key mechanisms of action in the Myasthenia Gravis pipeline drugs market are Complement C5 Inhibitor, IgG Receptor FcRn Large Subunit p51 Inhibitor, Cells Expressing B Lymphocyte Antigen CD20 Inhibitor, Acetylcholinesterase Inhibitor, Complement Factor D Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Inhibitor, and 5-Hydroxytryptamine Receptor 3 Inhibitor.
-
What are the key routes of administration in the Myasthenia Gravis pipeline drugs market?
The key routes of administration in the Myasthenia Gravis pipeline drugs market are Subcutaneous, Intravenous, Oral, Inhalational, Intravenous Drip, Ophthalmic, and Parenteral.
-
What are the key molecule types in the Myasthenia Gravis pipeline drugs market?
The key molecule types in the Myasthenia Gravis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Modified Cell Therapy, Synthetic Peptide, and Biologic.
-
What are the major companies in the Myasthenia Gravis pipeline drugs market?
The major companies in the Myasthenia Gravis pipeline drugs market are Akari Therapeutics Plc (Akari), Alexion Pharmaceuticals Inc (Alexion), Alpha Cancer Technologies Inc (ACT), Amneal Pharmaceuticals Inc (Amneal), Johnson and Johnson, and Argenx SE (argenx).
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Immunology reports